NewLink Genetics
NewLink Genetics, a biopharmaceutical company, develops therapeutic and diagnostic agents for patients with cancer and infectious diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$30—45m (Dealroom.co estimates Jul 2009.)
Ames Iowa (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | - | 28.0m | 13.0m | 40.0m | - |
| % growth | - | - | (54 %) | 208 % | - |
| EBITDA | - | (71.0m) | (61.0m) | (55.0m) | (44.0m) |
| % EBITDA margin | - | (254 %) | (469 %) | (138 %) | - |
| Profit | - | (72.0m) | (53.0m) | (4.0m) | (44.0m) |
| % profit margin | - | (257 %) | (408 %) | (10 %) | - |
| R&D budget | 48.4m | 37.4m | - | - | - |
| R&D % of revenue | - | 134 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $850k | Series A | |
| N/A | $8.2m | Series B | |
$17.0m | Series C | ||
| N/A | $7.5m | Series D | |
| N/A | N/A | IPO | |
| Total Funding | $33.5m | ||
Related Content
Recent News about NewLink Genetics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.